Перевод статьи Van Oudheusden LJ, Scholte HR 2 Efficacy of carnitine in the treatment o.doc

Van Oudheusden L.J.1, Scholte H.R.2 Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. Prostaglandins, Leukotrienes and Essential FattyAcids 2002; 67(1): 3338. . , . (). , (), , , , -, . 13 24 , , ( 0,02). 13 24 , ( 0,05). , ( 0,0001). ( 0,0001). . , , ( 0,03) ( 70 /), ( -GT U/), . 2. 3- / . 3. , . 4. , , . 5. , . 6. . . : , (), 120 , () 20, 39 . , 30 % . , . 30 26. : -, -. 8 . L- 6 /20 . . 100 / , 4 . 8, 16 24- , , , , , , , , , , , -, , 24. 24- . . 1. 22 26, . . (. 1) : , . 18. , 13 ( 0,02). , 12 ( 0,02) (. 3). 11 . ( 0,0001) : ( 0,0001), ( 0,01) ( 0,0001); (. 4). ( 0,03). ( 0,05) (. 5). 2065 % (848 ) , . . . , . . , , , . 20 24 . 6 , , 19 . 22, 23, 5, - 8, 24. , , 25. 26. , , , . , , , . , . (a) Verhulst et al. 18. 1. 1. (n = 579) (n = 26) ( ) ( ) ( ) ( ) 21,3 (14,0)04068,8 (20,3)30101 0,0001 3,2 (2,8)01010,8 (2,6)715 0,00011,3 (1,4)053,5 (2,9)011 0,001 7,0 (5,4)02023,1 (5,8)1436 0,0001 2. N = 26 ( ) (/)42,6 (7,8)25,257,3 (/)4,8 (1,2)2,98,4 3. = 24 13 (54 %)12 (50 %)2 (13 %)4 (17 %)24,764,00df 11P 0,02 0,05 4. ( ) , = 13 33,9 (6,6)2347 0,0001 6,6 (2,9)313 0,00011,3 (1,4)04 0,01 12,7 (5,5)723 0,0001 , = 8 65,7 (22,7)3694= 0,4 10,5 (3,0)715= 0,44,1 (2,9)19= 0,7 22,0 (6,8)1430= 0,3 5. (n = 13) (n = 8) ( ) ( ) (/) 42,3 (7,5)32,257.339,3 (8,1)25,249,10,2 81,0 (13,2)62,510668,9 (11,9)49,684,1 0,03 (/) 4,8 (1,9)3,58,44,4 (1,1)2,96,40,3 11,8 (4,6)5,618,58,6 (2,9)3,913,7 0,051. Mercugliano M. What is attention deficit/hyperactivity disorder? Pediatr Clin N Am 1999; 5: 831843.2. Hechtman L. Assessment and diagnosis of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000; 9: 481498.3. Elia J., Ambrosini P.J., Rapoport J.L. Treatment of attentiondeficit-hyperactivity disorder. N Engl J Med 1999; 340: 780788.4. Spencer T., Biederman J., Wilens T. et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycles. J Am Acad Child Adolesc Psychiatry 1996; 35(4): 409432.5. Arduini A., Denisova N., Virmani A., Avrova N., Federici G., Arrigoni-Martelli E. Evidence for the involvement of carnitinedependent long-chain acyltransferases in neuronal triglyceride and phospholipid fatty acid turnover. J Neurochem 1994; 62: 15301538.6. Burlina A.P., Sershen H., Debler E.A., Lajtha A. Uptake of acetyl-L-carnitine in the brain. Neurochem Res 1989; 14: 489493.7. Kuratsune H., Watanabe Y., Yamaguti K. et al. High uptake of 2-11C acetyl-L-carnitine into the brain: a PET study. Biochem Biophys Res Commun 1997; 13: 488493.8. Infante J.P., Huszagh V.A. Secondary carnitine deficiency and impaired docosahexaenoic (22:6n-3) acid synthesis: a common denominator in pathophysiology of diseases of oxidative phosphorylation and beta-oxidation. FEBS Lett 2000; 468: 15.9. Ricciolini R., Scalibastri M., Kelleher J.K., Carminati P., Calvani M., Arduini A. Role of acetyl-L-carnitine in rat brain lipogenesis: implications for polyunsaturated fatty acid biosynthesis. J Neurochem 1998; 71: 25102517.10. Calvani M., Arrigoni-Martelli E. Attenuation by acetyl-L-carnitine of neurological damage and biochemical derangement following brain ischemia and reperfusion. Int J Tissue React 1999; 21: 16.11. Aureli T., Miccheli A., Di Cocco M.E. et al. Effect of acetyl-L-carnitine on recovery of brain phosphorus metabolites and lactic level during reperfusion after cerebral ischemia in the rat-study by 13P- and 1H-NMR spectroscopy. Brain Res 1994; 643: 9299.12. Castorina M., Ferraris L. Acetyl-L-carnitine affects aged brain receptorial system in rodents. Life Sci 1994; 54: 12051214.13. Ricciolini R., Scalibastri M., Sciarroni A.F., et al. The carnitine system and acyl trafficking in CNS. In: Teelkens A., Korf J., eds. Neurochemistry: Cellular, Molecular and Clinical Aspects. New York: Plenum, 1997; 10711076.14. DellAnna M.E., Luvone L., Calzolari S., Geloso M.C. Effect of acetyl-L-carnitine on hyperactivity and spatial memory deficits on rats exposed to neonatal anoxia. Neurosci Lett 1997; 223: 201205.15. Torrioli M. G., Vernacotola S., Mariotti P. et al. Double blind placebo controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. Am J Med Gen 1999; 87: 366368.16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn (DSIM IV). Washington, DC: American Psychiatric Association, 1994.17. Achenbach T.M. Manual for the Child Behavior Checklist/4-18 and 1991 profile. Burlington, USA: University of Vermont, Department of Psychiatry, 1991.18. Verhulst F.C., van der Ende J., Koot H.M. Manual for the CBCL 14-18 (Dutch version). Rotterdam, The Netherlands: Department for Child and Youth Psychiatry, Sophia Childrens Hospital, University Hospital Rotterdam, Erasmus University Rotterdam. 1996.19. Boer F., Buitelaar J.K., Daalen E.V., GunningW.B., Minderaa R.B., Westermann G.M.A. Richtlijnen Diagnostiek en Behandeling ADHD. Amsterdam: Boom, Dutch Psychiatric Association, 1999.20. Conners C.K. The Conners rating scales: use in clinical assessment, treatment planning and research. In: Maruish M.E., ed. Use of Psychological Testing for Treatment Planning and Outcome Assessment. Hillsdale, NJ, USA: L. Erlbaum Associates, 1994.21. Vreken P., Van Lint A.E.M., Bootsma A.H., Overmars H.,Wanders R.J.A., van Gennip A.H. Quantitative plasma acylcarnitine analysis using electrospray tandem mass spectrometry for the diagnosis of organic acidemias and fatty-acid oxidation defects. J Inher Metab Dis 1999; 22: 302306.22. Famularo G., De Simone C. A new era for carnitine? Immunol Today 1995; 16: 211213.23. Hulsmann E.C. Carnitine against ischemia and liposaccharide toxicity. In: De Simone C., Famularo G., eds. Carnitine Today. New York: Springer, 1997; 163169.24. Infante J.P., Huszagh V.A. On the molecular etiology of decreased arac